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Abstract 
Perforation of the small intestine is the most lethal complication following induction 
chemotherapy for enteropathy-associated T-cell lymphoma (EATL). We report a case of 
EATL with a near perforated jejunal ulcer, and suggest a novel approach towards its 
management. Surgical resection followed by aggressive chemotherapy should limit 
chemotherapy-associated gastrointestinal toxicity, thus allowing patients to receive 
adequate dose and duration of chemotherapy. The presented case highlights potential 
benefits of surgical intervention prior to chemotherapy for EATL. 
 
Introduction 
Recent epidemiologic studies have shown that celiac disease (CD) is more common 
than previously thought and may affect approximately 1% of the general population [1]. 
Enteropathy-associated T-cell lymphoma (EATL), a rare but well-documented 
complication of CD, is a high-grade T-cell non-Hodgkin lymphoma (NHL) of the small 
intestine that is specifically associated with CD [2]. This potentially treatable tumor, 
which may be a significant subtype of NHL (fifth most common cancer in the United 
States) [1], has attracted renewed interest. Small bowel obstruction (SBO) is a rare initial 
presentation of intestinal lymphoma or CD, and it is even rarer in the case of EATL [1]. 
In most cases, these lymphomas behave aggressively, and their prognoses are typically 
grim which may be related to delayed diagnoses due to non-specific symptoms, lack of 
conclusive imaging and a low index of clinical suspicion.  
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Case Report 
At our hospital, we performed an exploratory laparotomy and segmental small bowel resection in a 
72-year-old man with a high-grade SBO. Intraoperatively, a near perforated ulcerative tumor in the 
proximal jejunum was identified as the obstructive etiology. Histopathology of the bowel adjacent to the 
tumor showed effacement of normal villous architecture (villous atrophy), the degree of which was 
consistent with long-standing but asymptomatic CD. The tumor was a high-grade NHL that was 
comprised of highly atypical lymphoid cells confirmed as T cells (immunostaining: positive for CD3 and 
CD45RO; negative for B-cell markers CD20 and CD30). Serological tests yielded strong evidence of 
anti-human tissue transglutaminase IgA, anti-endomysial IgA, and antigliadin IgG and IgA-findings 
consistent with untreated CD. Postoperatively, the patient was administered intensive chemotherapy 
consisting of 8 courses of CHOP (cyclophosphamide, adriamycin, oncovin and prednisolone). Re-
staging with computed tomography (CT) scan, small bowel contrast study and upper gastrointestinal 
(UGI) endoscopy with random biopsies at 6-month intervals have revealed no evidence of recurrence. A 
repeat PET scan demonstrated an ongoing complete response. At 3½-years of follow-up, the patient 
remains disease-free. 
Discussion 
The term EATL was first introduced by the International Lymphoma Study Group 
(ILSG) to denote its association with CD, and EATL is classified as ‘enteropathy-type 
intestinal T-cell lymphoma’ by the World Health Organisation (WHO) [3]. EATL, a rare 
form of T-cell lymphoma (<1% of all NHLs), usually occurs in the setting of refractory 
CD (RCD) with an incidence that is about 20 times higher than that for the general 
population [4, 5]. This corresponds to an incidence rate of 7–10% in patients with 
long-standing CD [6]. However, patients with CD who are adherent to a gluten-free diet 
for at least 1–5 years and have recovered small bowel architecture have an EATL 
lifetime-risk comparable to that of the normal population [7]. 
Occasionally, CD is identified following the diagnosis of lymphoma since the disease 
remains asymptomatic [1, 2]. The median age at diagnosis of EATL is 60 years, and there 
is a slight male preponderance. Patients with CD typically suffer from chronic or 
recurrent abdominal pain, diarrhea, or weight loss; whereas some may manifest non-
specific symptoms for years or present with an acute bowel perforation, obstruction, or 
hemorrhage. Since EATL is often disseminated at diagnosis, extraintestinal 
manifestations of the disease are seen in about 20% of cases. EATL usually presents as 
multifocal, circumferential ulcers localized to the jejunum or proximal
 ileum. The 
neoplastic cells are neither cytologically abnormal nor do they form tumor masses, which 
may cause a delayed diagnosis [8, 9]. Typically, EATLs reveal tumor cells that are CD3+, 
CD5–, CD7+, CD8–/+, CD4– and CD103+. Many cases contain a varying population of 
cells that are CD30+. In tumors with a high proportion of small and medium-sized cells, 
the cells are CD3+, CD8+ and CD30–. 
The natural history of EATL is generally unfavorable. Approximately 50% of patients 
require laparotomy for complications of hemorrhage, perforation, or obstruction [10]. 
The high risk of intestinal perforation is especially seen with the commencement of 
standard anti-lymphoma chemotherapy due to the multifocal nature of bowel disease, 
poor nutrition and tissue integrity. 
The suspicion of EATL should prompt an extensive diagnostic work-up that may 
include small bowel series, CT scan with enteroclysis, and total endoscopy – push or 
wireless video-capsule endoscopy (VCE) [11]. VCE is vital in the diagnostic work-up of 
complicated CD, particularly in cases with suspected RCD or EATL. VCE enables 
assessment of the extent of small bowel involvement and detection of overt though often  
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small neoplasms. It also assists in planning further diagnostic procedures, particularly 
enteroscopy, which are necessary to achieve a precise tissue diagnosis [12]. A prospective 
study comparing 
18F-FDG PET scan to conventional CT for the detection of EATL in 
patients with RCD showed that 
18F-FDG PET was better at discriminating between RCD 
and EATL and more sensitive and specific than CT scan (100 vs. 87% and 90 vs. 53%, 
respectively) [13]. 
Anthracyclin-based chemotherapy is the mainstay treatment of overt EATL, and 
CHOP or CHOP-like regimens were used most commonly in the 2 largest reported series 
[10, 14]. However, the outcomes of both series were poor with 1-year and 5-year survival 
rates in the range of 31–39% and 11–20%, respectively. In a prospective study of 35 
intestinal T-cell lymphoma patients treated with 6 cycles of CHOP, the cumulative 2-year 
survival was 28% [15],
 and in another series of EATL patients the survival at 30 months 
was only 13% [16]. In most EATL cases, multimodal therapy comprising of 
chemotherapy, radiation, and surgery can result in improved survival rates. Our review of 
literature revealed an association between intestinal perforations at the tumor site and 
initiation of chemotherapy, which may be related to lack of vigorous desmoplastic 
response in lymphoma. Four studies [14, 15, 17, 18] evaluating management options in 
EATL and other intestinal lymphomas have documented intestinal perforations upon 
commencement of primary chemotherapy in a high percentage of cases.  
Gale et al. [14] reported the largest
 series of 31
 patients with EATL. Twenty-four 
patients underwent combination chemotherapy, and grade 3 and 4 toxicities restricted 
more than half of the patients from completing chemotherapy. In 3 out of 4 patients who 
suffered small bowel
 perforation, it occurred after the first cycle of
 chemotherapy (at 1, 2, 
and 4 days) and proved fatal, and after 3 cycles in
 the fourth. In addition,
 a gastrointestinal 
bleed, a postoperative wound infection and an enterocolic fistula occurred in 3 separate 
patients, and 6 others encountered episodes of neutropenic
 sepsis following initiation of 
chemotherapy. Wöhrer et al. [17] reported that 2 out of 10 EATL patients initiated on 
CHOP regimen underwent emergent surgeries for intestinal perforations. In the series by 
Wada et al. [18], emergency operations performed following spontaneous gastrointestinal 
perforations that had occurred within 2 weeks of initiating chemotherapy in lymphoma 
patients were successful in 2, whereas the third succumbed to severe sepsis. In another 
study by Daum et al. [15], 80%
 (28 of 35) of all intestinal T-cell lymphomas were 
associated with histologic features
 of enteropathy in the uninvolved small bowel, hence 
were
 classified as EATL. Sixteen of these 28 patients (57.1%) required an emergent
 
laparotomy. Jantunen et al. [19]
 initiated combination high-dose chemotherapy with bone 
marrow transplant in five EATL patients – two died from transplant-related 
gastrointestinal toxicities and each of the surviving three relapsed/progressed within 0–14 
months. 
Bowel perforation is the second most common presentation (28.6%), after abdominal 
pain (66%), in primary intestinal lymphomas [20]. Uniquely, the high rate of 
chemotherapy-associated bowel perforation reported in patients with EATL makes it 
reasonable to consider surgery as the initial therapeutic modality prior to chemotherapy 
administration. The rarity of EATL accounts for the lack of a standard management 
scheme, and based on our experience and review of the literature we offer a novel 
algorithm (fig. 1). We suggest a multimodal approach that includes curative or debulking 
surgery to resect gross disease in all cases of EATLs, if tolerable, prior to chemotherapy. 
This may avoid chemotherapy-related bowel perforation, thus allowing completion of 
chemotherapy in most cases. Chemotherapy should be reserved as an adjuvant following 
resection, and long-term survival can be expected with its use. A recent series reported  
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sustained complete response in 66% of EATL patients who underwent surgical resection 
followed by combination chemotherapy and autologous stem cell transplant [21]. Follow-
up must include UGI endoscopy and random biopsy at 6-month intervals. PET scan 
offers significant advantage in surveillance due to its ability to detect both nodal and 
extra-nodal involvement, including focal bone involvement [22]. A prospective clinical 
trial is needed to assess the survival benefit from our proposal; however, the rarity of this 
disease makes that unlikely. 
 
 
 
 
 
Fig. 1. Proposed management algorithm for EATL. 
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